Skip to main content
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MIST ISIN · USU6005B1045 LEI · 549300P43IPGW3Q3Y026 US Manufacturing
Open in API
Filings indexed 346 across all filing types
Latest filing 2019-10-15 Board/Management Inform…
Country US United States of America
Listing US MIST

About Milestone Pharmaceuticals Inc.

https://www.milestonepharma.com

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company's lead investigational product is etripamil, a novel, fast-acting calcium channel blocker delivered as a nasal spray. This formulation is designed for patient self-administration to terminate episodes of certain heart rhythm disturbances outside of a hospital or emergency department setting. The primary indications under investigation for etripamil are paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), aiming to address unmet needs for acute, at-home treatment of these episodic conditions.

Recent filings

Filing Released Lang Actions
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 8, 2019, reporting the departure of the Chief Accounting Officer and the appointment of a new principal financial officer and principal accounting officer. The content focuses on changes in senior management positions, specifically officers of the company. There is no financial data, earnings information, or report publication mentioned. The document fits the category of announcements related to changes in the company's board of directors or senior management.
2019-10-15 English
4 Filing
Director's Dealing
2019-10-15 English
4 Filing
Director's Dealing
2019-10-03 English
SC 13D/A Filing
Major Shareholding Notification
2019-09-20 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 18, 2019, by Milestone Pharmaceuticals Inc. The key content is the resignation of a board member, Nilesh Kumar, from the Board of Directors and its committees. There is no financial data, earnings information, or report publication mentioned. The document specifically relates to a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3505 characters, which is short but contains substantive information about management changes, not just a report publication announcement or regulatory filing. Therefore, the correct classification is MANG with high confidence.
2019-09-20 English
4 Filing
Director's Dealing
2019-09-11 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.